SG11201707606RA - Designed ankyrin repeat domains with binding specificity for serum albumin - Google Patents
Designed ankyrin repeat domains with binding specificity for serum albuminInfo
- Publication number
- SG11201707606RA SG11201707606RA SG11201707606RA SG11201707606RA SG11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA
- Authority
- SG
- Singapore
- Prior art keywords
- serum albumin
- binding specificity
- ankyrin repeat
- repeat domains
- designed ankyrin
- Prior art date
Links
- 102000008102 Ankyrins Human genes 0.000 title 1
- 108010049777 Ankyrins Proteins 0.000 title 1
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162511 | 2015-04-02 | ||
| EP15162502 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707606RA true SG11201707606RA (en) | 2017-10-30 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707606RA SG11201707606RA (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (en) |
| EP (2) | EP3277711B9 (en) |
| JP (1) | JP6552636B2 (en) |
| KR (2) | KR102427117B1 (en) |
| CN (1) | CN107454904A (en) |
| AU (3) | AU2016240220B2 (en) |
| BR (1) | BR112017020986A2 (en) |
| CA (1) | CA2979602C (en) |
| CL (1) | CL2017002454A1 (en) |
| CO (1) | CO2017009954A2 (en) |
| ES (1) | ES2953482T3 (en) |
| HK (1) | HK1244009A1 (en) |
| IL (2) | IL276944B (en) |
| MX (2) | MX2022008302A (en) |
| MY (1) | MY179505A (en) |
| NZ (1) | NZ735803A (en) |
| PH (1) | PH12017501792A1 (en) |
| RU (1) | RU2769470C2 (en) |
| SA (1) | SA517390092B1 (en) |
| SG (1) | SG11201707606RA (en) |
| WO (1) | WO2016156596A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2371865T3 (en) | 2006-04-07 | 2017-10-23 | Aerpio Therapeutics Inc | Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof |
| CA2818969C (en) * | 2010-11-26 | 2020-04-14 | Molecular Partners Ag | Improved n-terminal capping modules for designed ankyrin repeat proteins |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| CN109790206A (en) | 2016-09-22 | 2019-05-21 | 分子组合公司 | Recombinant binding protein and application thereof |
| WO2019011167A1 (en) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | Bispecific recombinant protein |
| CA3073125A1 (en) * | 2017-08-18 | 2019-02-21 | Cambridge Enterprise Limited | Modular binding proteins |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| CA3139164A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| US20220298212A1 (en) | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| CA3138805A1 (en) | 2019-06-04 | 2020-12-10 | Johannes Schilling | Designed ankyrin repeat domain with improved stability |
| JP2022535564A (en) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | multiselective protein |
| IL293698A (en) | 2019-12-11 | 2022-08-01 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins and their generation and use |
| JP2023506763A (en) | 2019-12-11 | 2023-02-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | Recombinant peptide-MHC complex binding proteins and their production and use |
| MX2022013945A (en) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses. |
| CN115996945A (en) * | 2020-05-14 | 2023-04-21 | 分子合作伙伴股份公司 | Recombinant CD40 binding proteins and uses thereof |
| CA3178785A1 (en) | 2020-05-14 | 2021-11-18 | Nicolo RIGAMONTI | Multispecific proteins |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| EP4263608A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Partners AG | Recombinant cd3 binding proteins and their use |
| WO2022130300A1 (en) | 2020-12-16 | 2022-06-23 | Molecular Partners Ag | Novel slow-release prodrugs |
| WO2022190018A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| WO2022190010A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| CA3211381A1 (en) | 2021-03-09 | 2022-09-15 | Matteo Bianchi | Novel darpin based multi-specific t-cell engagers |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN114957426B (en) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | SP6RARS and application thereof in preventing and treating cockroaches |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CA2585435A1 (en) | 2004-11-12 | 2006-05-18 | Bayer Schering Pharma Aktiengesellschaft | Recombinant newcastle disease virus |
| PL1888640T3 (en) | 2005-05-18 | 2012-08-31 | Ablynx Nv | Improved nanobodies against tumor necrosis factor-alpha |
| BRPI0613593A2 (en) | 2005-07-08 | 2011-01-18 | Univ Zuerich | filamentous phage display test method, phage or phagemid vector and phage or phagemid vector library |
| DK2402754T4 (en) | 2006-03-06 | 2023-08-28 | Amunix Operating Inc | Unstructured recombinant polymers and uses thereof |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| JP2013518853A (en) | 2010-02-05 | 2013-05-23 | アブリンクス エン．ヴェー． | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides containing the same |
| AR081361A1 (en) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A |
| ES2676403T3 (en) * | 2010-07-09 | 2018-07-19 | Affibody Ab | Polypeptides |
| CN103180737A (en) * | 2010-07-19 | 2013-06-26 | 霍夫曼-拉罗奇有限公司 | A method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| US20130236467A1 (en) * | 2010-11-24 | 2013-09-12 | Jeremy Griggs | Multispecific antigen binding proteins targeting hgf |
| CA2818969C (en) | 2010-11-26 | 2020-04-14 | Molecular Partners Ag | Improved n-terminal capping modules for designed ankyrin repeat proteins |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | Il4/il13 binding repeat proteins and uses |
| RU2014150224A (en) | 2012-06-28 | 2016-08-20 | Молекьюлар Партнерс Аг | DESIGNED PROTEIN WITH ANKIRIN REPEAT, BINDING WITH THE PLATFORM GROWTH FACTOR |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| JP6486908B2 (en) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | Designed ankyrin repeat protein that binds to hepatocyte growth factor |
-
2016
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/en active Search and Examination
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 ES ES16713904T patent/ES2953482T3/en active Active
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en active Application Filing
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/en active Pending
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en unknown
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/en active
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/en unknown
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en active Active
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/en active Active
- 2016-04-01 MX MX2017012485A patent/MX2017012485A/en unknown
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/en active IP Right Grant
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/en not_active Application Discontinuation
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 PH PH12017501792A patent/PH12017501792A1/en unknown
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/en unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/en unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/en unknown
-
2018
- 2018-03-12 HK HK18103392.8A patent/HK1244009A1/en unknown
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276944A (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
| IL263102A (en) | Single domain serum albumin binding protein | |
| HK1251650A1 (en) | Cellular based fret assay for the determination of simultaneous binding | |
| IL267894A (en) | Improved serum albumin binders | |
| IL267897A (en) | Improved serum albumin binders | |
| ZA201804317B (en) | Altered april binding antibodies | |
| DK3374392T3 (en) | IMPROVED SERUM ALBUM BINDING VARIABLE IMMUNGLOBULIN DOMAINS | |
| HK1250737A1 (en) | Antibody molecules which bind cd79 | |
| ZA201701912B (en) | Antigen binding proteins that bind cxcr5 | |
| ZA201706272B (en) | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES | |
| HK1231497A1 (en) | Vl antigen binding proteins exhibiting distinct binding characteristics vl | |
| IL256298A (en) | Multi-specific binding proteins | |
| ZA201701941B (en) | Antigen binding proteins that bind cxcr3 | |
| IL267318A (en) | Binding assay | |
| ZA201901862B (en) | Modified factor h binding protein | |
| HK1255409A1 (en) | Antibody binding agents that bind acinetobacter and uses thereof | |
| GB201614627D0 (en) | Antigen binding proteins | |
| GB201615588D0 (en) | TSLP Binding Proteins | |
| HUP1600456A2 (en) | Novel cell-based tnf-alpha binding assay | |
| IL235702A0 (en) | Compositions and methods for binding myelin binding proteins |